OxyContin Claims in Four Patents Infringed but Invalid; Fifth Patent’s Claims Found Indefinite

Purdue Pharma L.P. et al. v. Teva Pharmaceuticals, USA, Inc.

Case Number: 1:11-cv-02037-SHS (Dkt.149)

Judge Stein found that Teva’s ANDA product infringes U.S. Patents Nos. 7,674,799 (entitled “Oxycodone hydrochloride having less than 25 ppm 14–hydroxycodeinone”), 7,674,800 (same), and 7,683,072 (same), but that the asserted claims were invalid. He found the 7,776,314 patent (entitled “Abuse-proofed dosage system”) not infringed and indefinite. He found the 8,114,383 patent (entitled “Abuse-proofed dosage form”) infringed but invalid. These patents relate to the drug oxycodone, sold by Purdue as OxyContin.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.